How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world.
Biomarkers
Metastatic pancreatic ductal adenocarcinoma
Molecular selection
Palliative chemotherapy
Real-world data
Second-line treatment
Journal
World journal of clinical oncology
ISSN: 2218-4333
Titre abrégé: World J Clin Oncol
Pays: United States
ID NLM: 101549149
Informations de publication
Date de publication:
24 May 2022
24 May 2022
Historique:
received:
05
01
2022
revised:
01
04
2022
accepted:
05
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
ppublish
Résumé
As underlined in the minireview by Blomstrand
Identifiants
pubmed: 35662988
doi: 10.5306/wjco.v13.i5.417
pmc: PMC9153079
doi:
Types de publication
Journal Article
Langues
eng
Pagination
417-422Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Prof. Scartozzi reports associations with Amgen, Sanofi, MERCK SHARP DOHME, Eisai, Merck, and Bayer, outside the submitted work.
Références
Expert Opin Ther Targets. 2021 Nov;25(11):987-1005
pubmed: 34806517
World J Clin Oncol. 2021 Sep 24;12(9):787-799
pubmed: 34631442
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Tumori. 2021 Dec;107(6):550-555
pubmed: 33243068
Cancer Treat Rev. 2019 Dec;81:101926
pubmed: 31739115
Eur J Cancer. 2019 Feb;108:78-87
pubmed: 30654298
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
Br J Cancer. 2021 Nov;125(10):1321-1332
pubmed: 34262146